Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1500
- Registration Number
- NCT06113692
- Locations
- π©π°
Aarhus University Hospital, Aarhus, Denmark
π³π΄University of Oslo, Oslo, Norway
πͺπΈIDIAP Jordi Gol, Barcelona, Spain
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 346
- Registration Number
- NCT06097299
- Locations
- πΊπΈ
Velocity Clinical Research, Phoenix, Phoenix, Arizona, United States
πΊπΈHeadlands Research - Scottsdale, Scottsdale, Arizona, United States
πΊπΈVelocity Clinical Research - Banning, Banning, California, United States
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, β₯50 Years of Age
- Conditions
- SARS-CoV-2Influenza
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8061
- Registration Number
- NCT06097273
- Locations
- πΊπΈ
Pinnacle Research Group-409 E 10th St, Anniston, Alabama, United States
πΊπΈAccel Research Site - Achieve - Birmingham, Birmingham, Alabama, United States
πΊπΈCullman Clinical Trials, Cullman, Alabama, United States
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
- Conditions
- Respiratory Syncytial Virus
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1150
- Registration Number
- NCT06067230
- Locations
- πΊπΈ
Lenzmeier Family Medicine - CCT - PPDS, Glendale, Arizona, United States
πΊπΈFoothills Research Center - CCT - PPDS, Phoenix, Arizona, United States
πΊπΈFiel Family & Sports Medicine - PC - CCT - PPDS, Tempe, Arizona, United States
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults β₯65 Years of Age
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Biological: PlaceboBiological: mRNA-1345Biological: Fluzone HD
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1900
- Registration Number
- NCT06060457
- Locations
- πΊπΈ
Scottsdale Clinical Trials, Scottsdale, Arizona, United States
πΊπΈHeadlands Research, Inc., Scottsdale, Arizona, United States
πΊπΈWest Coast Research LLC, Dublin, California, United States
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT06033261
- Locations
- πΊπΈ
Accel Clinical Sites Network - Cahaba Medical Care, Birmingham, Alabama, United States
πΊπΈNoble Clinical Research, Tucson, Arizona, United States
πΊπΈCedars-Sinai Medical Center/Carbon Health, Beverly Hills, California, United States
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From β₯18 Years of Age to <50 Years of Age
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 351
- Registration Number
- NCT05995275
- Locations
- π¬π§
Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
π¬π§University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
π¬π§Lakeside Healthcare Research, Corby, United Kingdom
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- Conditions
- Norovirus Acute Gastroenteritis
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1285
- Registration Number
- NCT05992935
- Locations
- πΊπΈ
ARK Clinical Research, LLC, Long Beach, California, United States
πΊπΈTekton Research, Inc - Longmont Center, Longmont, Colorado, United States
πΊπΈResearch Centers of America, Hollywood, Florida, United States
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
- Conditions
- Lyme Disease
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 807
- Registration Number
- NCT05975099
- Locations
- πΊπΈ
Clinical Research Consulting, LLC, Milford, Connecticut, United States
πΊπΈStamford Therapeutics Consortium, Stamford, Connecticut, United States
πΊπΈChase Medical Research, LLC, Waterbury, Connecticut, United States
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: mRNA-1018 for H5 OnlyBiological: mRNA-1018 for H7N9Biological: mRNA-1018 for H5 Only-CGBiological: mRNA-1018 for H5N8Biological: mRNA-1018 for H7 Only
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1504
- Registration Number
- NCT05972174
- Locations
- πΊπΈ
CenExel RCA, Hollywood, Florida, United States
π¬π§Velocity Clinical Research, North Finchley, United Kingdom
πΊπΈJohnson County Clin-Trials, Lenexa, Kansas, United States